Nuvation Bio (NUVB) Receivables: 2024-2025

Nuvation Bio's Receivables rose 66.43% to $6.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.4 million, marking a year-over-year change of. This contributed to the annual value of $16.3 million for FY2024, which is N/A change from last year.
As of Q2 2025, Nuvation Bio's Receivables stood at $6.7 million, which was up 22.24% from $5.5 million recorded in Q1 2025.
Nuvation Bio's 5-year Receivables high stood at $6.7 million for Q2 2025, and its period low was $4.0 million during Q2 2024.
Its 2-year average for Receivables is $5.1 million, with a median of $4.9 million in 2024.
Data for Nuvation Bio's Receivables shows a peak YoY surged of 66.43% (in 2025) over the last 5 years.
Nuvation Bio's Receivables (Quarterly) stood at $4.3 million in 2024, then surged by 66.43% to $6.7 million in 2025.
Its last three reported values are $6.7 million in Q2 2025, $5.5 million for Q1 2025, and $4.3 million during Q3 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Summit Therapeutics Inc.	1,387.71B	1,387.50B	-	-
2	BeOne Medicines Ltd.	458.68B	457.16B	1.15B	-
3	Vertex Pharmaceuticals Inc / Ma	102.37B	99.35B	-	-
4	Benitec Biopharma Inc.	65.38B	65.31B	-	-
5	Regeneron Pharmaceuticals, Inc.	60.67B	60.28B	-	-
6	Alnylam Pharmaceuticals, Inc.	60.53B	62.66B	-	-
7	Argenx Se	45.96B	50.00B	-	-
8	INSMED Inc	26.50B	27.40B	-	-
9	BioNTech SE	25.15B	17.24B	-	-
10	Nuvation Bio Inc.	1.42B	1.38B	2.26M	-